GLP-1 Agonists for Male Infertility: A Clinical Trial for Obese Men
Background
Obesity significantly impairs male fertility by negatively impacting sperm quality and hormone levels, making conception challenging. While weight loss through lifestyle changes is beneficial, adherence can be difficult. New GLP-1 receptor agonists like semaglutide and tirzepatide effectively promote weight loss and improve metabolic health. This multicenter clinical trial aims to rigorously evaluate if these drugs can safely and effectively improve fertility outcomes in obese men with infertility.
Results
As this study (NCT07179120) is currently NOT_YET_RECRUITING and scheduled to begin in 2026, no actual findings are available yet. However, the trial is designed to measure significant improvements in key fertility parameters. Researchers anticipate that both semaglutide and tirzepatide groups will demonstrate superior outcomes compared to the lifestyle intervention group. The primary outcome will assess changes in sperm concentration, motility, and morphology, alongside improvements in hormone levels (e.g., testosterone) and body weight. It is hypothesized that GLP-1 receptor agonist treatment will lead to a statistically significant increase in live birth rates or pregnancy rates, and a substantial reduction in body mass index (BMI) in the treatment arms. Secondary outcomes will include changes in metabolic markers and adverse event profiles, with results expected by 2027.
Why It Matters
Obesity-related male infertility is a growing concern, and current treatments often lack sustained efficacy or adherence. This trial holds the potential to identify a novel and effective pharmacological intervention for this challenging condition. If successful, this research could establish GLP-1 receptor agonists as a viable therapeutic option for obese men struggling with infertility, potentially integrating them into clinical guidelines. Positive results would pave the way for broader clinical adoption and further research into the underlying mechanisms of GLP-1 receptor agonists on male reproductive health.